Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

Iconic Therapeutics

Ophthamology

Biopharma company licensing a novel recominant protein called hI-con1, which binds tissue factor, thus triggering cells that selectively destroy pathologic nerovascular blood vessels.